CME Available: cme.auanet.org/URL/FOCUS263ONL

LEARNING OBJECTIVES:

After participating in this CME activity, participants will be able to:

1. Analyze emerging data in NMIBC and guideline updates to evaluate the impact of disease recurrence and treatment-related complications on current care pathways and patient outcomes.
2. Apply guideline-driven risk stratification in order to identify and select appropriate patients with high-risk NMIBC for optimal therapy sequencing and escalation of care.
3. Implement strategies for safe and effective integration of novel intravesical and systemic immunotherapies to strengthen multidisciplinary collaboration and shared decision-making between urology and medical oncology.
4. Develop patient-centered, evidence-informed care plans using guideline updates and real-world case examples, in order to address unmet needs, reduce recurrence risk, and improve quality of life for patients with NMIBC.

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from:

AstraZeneca

ImmunityBio

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

UroGen Pharma, Inc.